CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 49 enrolled
Drug / intervention
Pharmacy Delivered PrEP Interventionbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04393935
NCT04393935N/ACompleted
CompareCT.gov

Advancing Pre-exposure Prophylaxis (PrEP) Access in Pharmacies to Improve PrEP Uptake in Disadvantaged Areas

Emory University·interventional·Posted May 19, 2020·Updated May 28, 2025

In Brief

A clinical study evaluating Pharmacy Delivered PrEP Intervention for Human Immunodeficiency Virus. Completed, enrolled 49 participants across 1 site.

Detailed Summary

The proposed research will develop a culturally appropriate pharmacy pre-exposure prophylaxis (PrEP) delivery model for black men who have sex with men (BMSM) who live in high poverty, racial minority neighborhoods. Increasing access to PrEP through pharmacies has the potential to increase PrEP uptake among BMSM thereby reducing HIV incidence and racial inequities in HIV.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedMay 19, 2020
Enrollment StartMay 19, 2022
Primary CompletionMay 11, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 6.1 years ago

Interventions

Pharmacy Delivered PrEP Interventionbehavioral

Pharmacy client participants who are eligible and agree to the HIV test will be provided with a pre-packaged kit of a self-administered test for HIV and directed back to the private area of the pharmacy to perform their screening. Pharmacy client participants who test HIV negative will be provided with their results and be given a 30-day prescription for PrEP, culturally appropriate PrEP counseling and a follow-up appointment with a PrEP prescribing physician. Pharmacy client participants will be contacted after 3 months to determine whether they continued PrEP use.